Lenz Therapeutics, Inc. (LENZ)
NASDAQ:LENZ
Want to see LENZ full AI Analyst Report?
LENZ Stock Chart & Stats
$10.18
-$0.43(-1.58%)
At close: 4:00 PM EST
$10.18
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$6.61 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)862.26K
Market Cap
$236.73M
Enterprise Value$212.19M
Total Cash (Recent Filing)$258.38M
Total Debt (Recent Filing)$237.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 19, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding31,354,395
10 Day Avg. Volume1,008,792
30 Day Avg. Volume862,261
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)1.62
Price to Sales (P/S)24.15
P/FCF Ratio-6.59
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue10.11
Enterprise Value/Gross Profit11.09
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$32.20Price Target Upside216.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-3.93
Revenue Forecast (FY)$24.88M
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationClinical data showing greater efficacy, faster onset, and longer durability across a broader patient group positions Vizz as a best-in-class presbyopia therapy and provides clear differentiation points for prescribers.
Marketing EffectivenessDirect-to-consumer marketing featuring a prominent spokesperson generated strong consumer engagement and increased website traffic, supporting potential expansion of demand as awareness grows.
Prescriber AdoptionInitial adoption by many eye care professionals with a high rate of repeat prescriptions indicates meaningful prescriber interest that could support sustained sales growth.
Bears Say
Competitive PressureA competitor securing financing strengthens its commercial-launch capability, increasing competition for market share and potentially pressuring pricing and uptake.
Revenue Ramp And Valuation RiskAnalyst reduced valuation and forecasts to reflect a slower-than-expected sales ramp, signaling upside risk to near-term revenue execution and the stock price.
Safety MonitoringReports of ocular adverse events, including retinal issues and transient eye redness, create investor caution and necessitate ongoing safety monitoring that could slow adoption.
LENZ Therapeutics News
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $6.61 and its highest was $50.40 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $236.73M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 83 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$1.32 earnings per share for the quarter, missing the consensus estimate of -$1.048 by -$0.272.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -1.07.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 31,354,395 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$1.32 in its last earnings report, missing expectations of -$1.048. Following the earnings report the stock price went down -20.821%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (216.31% Upside)
$32.20 (216.31% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 50.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $365.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.49%
12-Months-Change
Fundamentals
Return on Equity
-46.82%
Trailing 12-Months
Asset Growth
35.42%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced encouraging early commercial and clinical signals against clear near-term execution and financial challenges. Highlights include meaningful prescription growth (25k prescriptions, +19% QoQ), a large and growing prescriber base (10k+ prescribers), improving e-pharmacy refill patterns (two-thirds three-month packs), solid unit economics (≈$67 net per pack, ≈$60 net cash per unit), favorable early safety readouts, and a strong cash position (~$258M). Lowlights center on slower-than-expected new patient adoption, elevated SG&A and operating losses (Q1 SG&A $45M, net loss $41.5M), one-time cost-of-sales charges, and remaining uncertainty around durable refill dynamics until cohorts mature. Management outlined concrete commercialization actions (field messaging, DTC optimization, direct-to-practice selling, manufacturing improvements) intended to address adoption friction, but the launch remains early and will require demonstrated momentum in upcoming quarters.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$32.20
▲(216.31% Upside)
Technical Analysis
Ownership Overview
15.24% Insiders
18.41% Mutual Funds
50.72% Other Institutional Investors
7.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---